Opioid REMS: FDA Sees No Clear Verdict On Risk Management Program's Impact
This article was originally published in The Pink Sheet Daily
Executive Summary
Agency raises generalizability concerns with prescriber and patient surveys conducted to assess impact of REMS for extended-release/long-acting opioids; surveillance data provide little evidence the REMS has resulted in changes in safety outcomes but also do not demonstrate the program has been ineffective.
You may also be interested in...
Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation
The latest drug development news and highlights from our FDA Performance Tracker.
FDA's Opioid REMS Review Puts Brakes On Mandatory Education Push
Requiring training and certification for extended-release opioids would involve at least 320,000 prescribers and impact 21 million outpatient prescriptions, reviewers note in a briefing memo that is more skeptical of the mandatory approach than FDA's leadership has been.
Oncopeptides’ Pepaxto Needs New Study To Identify Population That Will Benefit, FDA Panel Says
Advisory committee votes 14-2 that melflufen’s benefit-risk profile is unfavorable in the current accelerated approval indication for fifth-line treatment of multiple myeloma; panel rejects sponsor’s attempt to rely on post hoc analyses to 'carve out' a subpopulation that, it asserts, is responsible for negative overall survival trend in OCEAN confirmatory trial.